排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Marielle E. Yohe Christine M. Heske Elizabeth Stewart Peter C. Adamson Nabil Ahmed Cristina R. Antonescu Eleanor Chen Natalie Collins Alan Ehrlich Rene L. Galindo Berkley E. Gryder Heidi Hahn Sharon Hammond Mark E. Hatley Douglas S. Hawkins Madeline N. Hayes Andrea Hayes‐Jordan Lee J. Helman Simone Hettmer Myron S. Ignatius Charles Keller Javed Khan David G. Kirsch Corinne M. Linardic Philip J. Lupo Rossella Rota Jack F. Shern Janet Shipley Sivasish Sindiri Stephen J. Tapscott Christopher R. Vakoc Leonard H. Wexler David M. Langenau 《Pediatric blood & cancer》2019,66(10)
Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan. 相似文献
2.
James V. Tricoli PhD Lisa A. Boardman MD Rajesh Patidar PhD Sivasish Sindiri PhD Jin S. Jang PhD William D. Walsh BA Paul M. McGregor BA III Corinne E. Camalier MA Michele G. Mehaffey MA Wayne L. Furman MD Armita Bahrami MD P. Mickey Williams PhD Chih‐Jian Lih PhD Barbara A. Conley MD Javed Khan MD 《Cancer》2018,124(5):1070-1082
3.
1